Biodexa Pharmaceuticals (BDRX) Retained Earnings (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Retained Earnings of -$207.3 million for Q4 2025, down 0.79% sequentially from -$205.6 million in Q2 2025, and down 7.35% YoY from -$223.7 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Retained Earnings (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Retained Earnings for 13 years, with the latest figure at -$207.3 million in Q4 2025.
- Quarterly Retained Earnings fell 7.35% year-over-year to -$207.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$207.3 million (down 7.35% YoY) and the FY2025 annual result came in at -$205.4 million, down 6.4% from the prior year.
- Retained Earnings slipped to -$207.3 million in Q4 2025 per BDRX's latest filing, from -$205.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$158.7 million in Q4 2022 and troughed at -$207.3 million in Q4 2025.
- A 5-year average of -$181.7 million and a median of -$177.6 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2021 and 2022: Retained Earnings fell 20.04% in 2021, then advanced 7.86% in 2022.
- Over 5 years, Retained Earnings stood at -$172.3 million in 2021, then rose by 7.86% to -$158.7 million in 2022, then retreated by 13.19% to -$179.7 million in 2023, then dropped by 7.45% to -$193.1 million in 2024, then slipped by 7.35% to -$207.3 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$207.3 million, -$205.6 million, and -$193.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | -207.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -207.25 Mn |
| Jun 30, 2025 | -205.62 Mn |
| Dec 31, 2024 | -193.07 Mn |
| Jun 30, 2024 | -186.66 Mn |
| Dec 31, 2023 | -179.68 Mn |
| Jun 30, 2023 | -173.91 Mn |
| Dec 31, 2022 | -158.74 Mn |
| Jun 30, 2022 | -164.67 Mn |
| Dec 31, 2021 | -172.28 Mn |
| Jun 30, 2021 | -175.48 Mn |
| Dec 31, 2020 | -161.67 Mn |
| Jun 30, 2020 | -146.19 Mn |
| Dec 31, 2019 | -128.37 Mn |
| Jun 30, 2019 | -121.06 Mn |
| Dec 31, 2018 | -115.45 Mn |
| Jun 30, 2018 | -117.38 Mn |
| Dec 31, 2017 | -99.12 Mn |
| Jun 30, 2017 | -86.73 Mn |
| Dec 31, 2016 | -73.49 Mn |
| Jun 30, 2016 | -67.90 Mn |